

Sepsis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

<https://marketpublishers.com/r/S64F0AEE1F68EN.html>

Date: May 2024

Pages: 131

Price: US\$ 6,499.00 (Single User License)

ID: S64F0AEE1F68EN

Abstracts

The 7 major sepsis markets reached a value of US\$ 438.4 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US\$ 907.3 Million by 2034, exhibiting a growth rate (CAGR) of 6.84% during 2024-2034.

The sepsis market has been comprehensively analyzed in IMARC's new report titled "Sepsis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Sepsis refers to a potentially life-threatening condition that occurs when the body's response to infection becomes dysregulated and triggers a systemic inflammatory response. This disease can result in a series of alterations, which damage multiple organ systems, causing them to fail and sometimes even leading to death. The symptoms of the ailment can vary but often include fever, rapid heart rate, shivering, lightheadedness, difficulty breathing, mental confusion, etc. Individuals suffering from sepsis may also experience organ dysfunction, such as decreased urine output and abnormal liver function. In severe cases, this illness can lead to septic shock, characterized by extremely low blood pressure and poor organ perfusion. The diagnosis of this sepsis typically involves a combination of clinical evaluation, laboratory tests, and imaging studies. A healthcare practitioner may perform a complete blood count to assess the levels of white blood cells, red blood cells, and platelets, as well as to measure inflammatory markers, such as C-reactive protein and procalcitonin. Additionally, numerous imaging studies, like X-rays, ultrasounds, computed tomography, etc., might be adopted to identify the source of infection.

The increasing cases of bacterial, viral, and fungal infections, that can trigger chain reactions throughout the body are primarily driving the sepsis market. In addition to this, the expanding geriatric population, who are prone to chronic health conditions and a weakened immune system, is also bolstering the market growth. Furthermore, the

widespread adoption of effective drugs, including anti-anxiety medications, antipyretics, anticoagulants, etc., for managing the symptoms of the ailment is acting as another significant growth-inducing factor. Additionally, the inflating utilization of vasopressor support therapy to increase blood pressure and maintain adequate organ perfusion among patients is also augmenting the market growth. Moreover, the escalating demand for central venous catheters, which enable the administration of therapeutic agents directly into the bloodstream, thereby ensuring prompt and targeted treatment, is further creating a positive outlook for the market. Apart from this, the emerging popularity of integrin inhibitors, like cilengitide, on account of their numerous advantages, such as preserving endothelial cell lining and preventing disease progression, is expected to drive the sepsis market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the sepsis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for sepsis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the sepsis market in any manner.

Time Period of the Study

Base Year: 2023

Historical Period: 2018-2023

Market Forecast: 2024-2034

Countries Covered

United States

Germany

France

United Kingdom

Italy

Spain

Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario

Historical, current, and future performance of the sepsis market

Historical, current, and future performance of various therapeutic categories in the market

Sales of various drugs across the sepsis market

Reimbursement scenario in the market

In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current sepsis marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug overview

Mechanism of action

Regulatory status

Clinical trial results

Drug uptake and market performance

Late-Stage Pipeline Drugs

Drug overview

Mechanism of action

Regulatory status

Clinical trial results

Drug uptake and market performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

How has the sepsis market performed so far and how will it perform in the coming years?

What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?

What was the country-wise size of the sepsis market across the seven major markets in 2023 and what will it look like in 2034?

What is the growth rate of the sepsis market across the seven major markets and what will be the expected growth over the next ten years?

What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (2018-2034) of sepsis across the seven major markets?

What is the number of prevalent cases (2018-2034) of sepsis by age across the seven major markets?

What is the number of prevalent cases (2018-2034) of sepsis by gender across the seven major markets?

How many patients are diagnosed (2018-2034) with sepsis across the seven major markets?

What is the size of the sepsis patient pool (2018-2023) across the seven major markets?

What would be the forecasted patient pool (2024-2034) across the seven major markets?

What are the key factors driving the epidemiological trend of sepsis?

What will be the growth rate of patients across the seven major markets?

Sepsis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?

What are the key pipeline drugs and how are they expected to perform in the coming years?

How safe are the current marketed drugs and what are their efficacies?

How safe are the late-stage pipeline drugs and what are their efficacies?

What are the current treatment guidelines for sepsis drugs across the seven major markets?

Who are the key companies in the market and what are their market shares?

What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the sepsis market?

What are the key regulatory events related to the sepsis market?

What is the structure of clinical trial landscape by status related to the sepsis market?

What is the structure of clinical trial landscape by phase related to the sepsis market?
What is the structure of clinical trial landscape by route of administration related to the sepsis market?

Contents

?1 Preface

2 SCOPE AND METHODOLOGY

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
 - 2.3.1 Primary Sources
 - 2.3.2 Secondary Sources
- 2.4 Market Estimation
 - 2.4.1 Bottom-Up Approach
 - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

3 EXECUTIVE SUMMARY

4 SEPSIS - INTRODUCTION

- 4.1 Overview
- 4.2 Regulatory Process
- 4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
- 4.4 Market Overview (2018-2023) and Forecast (2024-2034)
- 4.5 Competitive Intelligence

5 SEPSIS - DISEASE OVERVIEW

- 5.1 Introduction
- 5.2 Symptoms and Diagnosis
- 5.3 Pathophysiology
- 5.4 Causes and Risk Factors
- 5.5 Treatment

6 PATIENT JOURNEY

7 SEPSIS - EPIDEMIOLOGY AND PATIENT POPULATION

- 7.1 Epidemiology - Key Insights

7.2 Epidemiology Scenario - Top 7 Markets

7.2.1 Epidemiology Scenario (2018-2023)

7.2.2 Epidemiology Forecast (2024-2034)

7.2.3 Epidemiology by Age (2018-2034)

7.2.4 Epidemiology by Gender (2018-2034)

7.2.5 Diagnosed Cases (2018-2034)

7.2.6 Patient Pool/Treated Cases (2018-2034)

7.3 Epidemiology Scenario - United States

7.3.1 Epidemiology Scenario (2018-2023)

7.3.2 Epidemiology Forecast (2024-2034)

7.3.3 Epidemiology by Age (2018-2034)

7.3.4 Epidemiology by Gender (2018-2034)

7.3.5 Diagnosed Cases (2018-2034)

7.3.6 Patient Pool/Treated Cases (2018-2034)

7.4 Epidemiology Scenario - Germany

7.4.1 Epidemiology Scenario (2018-2023)

7.4.2 Epidemiology Forecast (2024-2034)

7.4.3 Epidemiology by Age (2018-2034)

7.4.4 Epidemiology by Gender (2018-2034)

7.4.5 Diagnosed Cases (2018-2034)

7.4.6 Patient Pool/Treated Cases (2018-2034)

7.5 Epidemiology Scenario - France

7.5.1 Epidemiology Scenario (2018-2023)

7.5.2 Epidemiology Forecast (2024-2034)

7.5.3 Epidemiology by Age (2018-2034)

7.5.4 Epidemiology by Gender (2018-2034)

7.5.5 Diagnosed Cases (2018-2034)

7.5.6 Patient Pool/Treated Cases (2018-2034)

7.6 Epidemiology Scenario - United Kingdom

7.6.1 Epidemiology Scenario (2018-2023)

7.6.2 Epidemiology Forecast (2024-2034)

7.6.3 Epidemiology by Age (2018-2034)

7.6.4 Epidemiology by Gender (2018-2034)

7.6.5 Diagnosed Cases (2018-2034)

7.6.6 Patient Pool/Treated Cases (2018-2034)

7.7 Epidemiology Scenario - Italy

7.7.1 Epidemiology Scenario (2018-2023)

7.7.2 Epidemiology Forecast (2024-2034)

7.7.3 Epidemiology by Age (2018-2034)

- 7.7.4 Epidemiology by Gender (2018-2034)
- 7.7.5 Diagnosed Cases (2018-2034)
- 7.7.6 Patient Pool/Treated Cases (2018-2034)
- 7.8 Epidemiology Scenario - Spain
 - 7.8.1 Epidemiology Scenario (2018-2023)
 - 7.8.2 Epidemiology Forecast (2024-2034)
 - 7.8.3 Epidemiology by Age (2018-2034)
 - 7.8.4 Epidemiology by Gender (2018-2034)
 - 7.8.5 Diagnosed Cases (2018-2034)
 - 7.8.6 Patient Pool/Treated Cases (2018-2034)
- 7.9 Epidemiology Scenario - Japan
 - 7.9.1 Epidemiology Scenario (2018-2023)
 - 7.9.2 Epidemiology Forecast (2024-2034)
 - 7.9.3 Epidemiology by Age (2018-2034)
 - 7.9.4 Epidemiology by Gender (2018-2034)
 - 7.9.5 Diagnosed Cases (2018-2034)
 - 7.9.6 Patient Pool/Treated Cases (2018-2034)

8 SEPSIS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES

- 8.1 Guidelines, Management and Treatment
- 8.2 Treatment Algorithm

9 SEPSIS - UNMET NEEDS

10 SEPSIS - KEY ENDPOINTS OF TREATMENT

11 SEPSIS - MARKETED PRODUCTS

- 11.1 List of Sepsis Marketed Drugs Across the Top 7 Markets
 - 11.1.1 Giapreza (Angiotensin II) - La Jolla Pharmaceutical Company
 - 11.1.1.1 Drug Overview
 - 11.1.1.2 Mechanism of Action
 - 11.1.1.3 Regulatory Status
 - 11.1.1.4 Clinical Trial Results
 - 11.1.1.5 Sales Across Major Markets

Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.

12 SEPSIS - PIPELINE DRUGS

12.1 List of Sepsis Pipeline Drugs Across the Top 7 Markets

12.1.1 Interleukin 7 - Revimmune SAS

12.1.1.1 Drug Overview

12.1.1.2 Mechanism of Action

12.1.1.3 Clinical Trial Results

12.1.1.4 Safety and Efficacy

12.1.1.5 Regulatory Status

12.1.2 Cefiderocol - Shionogi

12.1.2.1 Drug Overview

12.1.2.2 Mechanism of Action

12.1.2.3 Clinical Trial Results

12.1.2.4 Safety and Efficacy

12.1.2.5 Regulatory Status

12.1.3 Nangibotide - Inotrem

12.1.3.1 Drug Overview

12.1.3.2 Mechanism of Action

12.1.3.3 Clinical Trial Results

12.1.3.4 Safety and Efficacy

12.1.3.5 Regulatory Status

12.1.4 Adrecizumab - Adrenomed

12.1.4.1 Drug Overview

12.1.4.2 Mechanism of Action

12.1.4.3 Clinical Trial Results

12.1.4.4 Safety and Efficacy

12.1.4.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

13. SEPSIS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS

14. SEPSIS – CLINICAL TRIAL LANDSCAPE

14.1 Drugs by Status

14.2 Drugs by Phase

14.3 Drugs by Route of Administration

14.4 Key Regulatory Events

15 SEPSIS - MARKET SCENARIO

15.1 Market Scenario - Key Insights

15.2 Market Scenario - Top 7 Markets

15.2.1 Sepsis - Market Size

15.2.1.1 Market Size (2018-2023)

15.2.1.2 Market Forecast (2024-2034)

15.2.2 Sepsis - Market Size by Therapies

15.2.2.1 Market Size by Therapies (2018-2023)

15.2.2.2 Market Forecast by Therapies (2024-2034)

15.3 Market Scenario - United States

15.3.1 Sepsis - Market Size

15.3.1.1 Market Size (2018-2023)

15.3.1.2 Market Forecast (2024-2034)

15.3.2 Sepsis - Market Size by Therapies

15.3.2.1 Market Size by Therapies (2018-2023)

15.3.2.2 Market Forecast by Therapies (2024-2034)

15.3.3 Sepsis - Access and Reimbursement Overview

15.4 Market Scenario - Germany

15.4.1 Sepsis - Market Size

15.4.1.1 Market Size (2018-2023)

15.4.1.2 Market Forecast (2024-2034)

15.4.2 Sepsis - Market Size by Therapies

15.4.2.1 Market Size by Therapies (2018-2023)

15.4.2.2 Market Forecast by Therapies (2024-2034)

15.4.3 Sepsis - Access and Reimbursement Overview

15.5 Market Scenario - France

15.5.1 Sepsis - Market Size

15.5.1.1 Market Size (2018-2023)

15.5.1.2 Market Forecast (2024-2034)

15.5.2 Sepsis - Market Size by Therapies

15.5.2.1 Market Size by Therapies (2018-2023)

15.5.2.2 Market Forecast by Therapies (2024-2034)

15.5.3 Sepsis - Access and Reimbursement Overview

15.6 Market Scenario - United Kingdom

15.6.1 Sepsis - Market Size

15.6.1.1 Market Size (2018-2023)

15.6.1.2 Market Forecast (2024-2034)

15.6.2 Sepsis - Market Size by Therapies

- 15.6.2.1 Market Size by Therapies (2018-2023)
- 15.6.2.2 Market Forecast by Therapies (2024-2034)
- 15.6.3 Sepsis - Access and Reimbursement Overview
- 15.7 Market Scenario - Italy
 - 15.7.1 Sepsis - Market Size
 - 15.7.1.1 Market Size (2018-2023)
 - 15.7.1.2 Market Forecast (2024-2034)
 - 15.7.2 Sepsis - Market Size by Therapies
 - 15.7.2.1 Market Size by Therapies (2018-2023)
 - 15.7.2.2 Market Forecast by Therapies (2024-2034)
 - 15.7.3 Sepsis - Access and Reimbursement Overview
- 15.8 Market Scenario - Spain
 - 15.8.1 Sepsis - Market Size
 - 15.8.1.1 Market Size (2018-2023)
 - 15.8.1.2 Market Forecast (2024-2034)
 - 15.8.2 Sepsis - Market Size by Therapies
 - 15.8.2.1 Market Size by Therapies (2018-2023)
 - 15.8.2.2 Market Forecast by Therapies (2024-2034)
 - 15.8.3 Sepsis - Access and Reimbursement Overview
- 15.9 Market Scenario - Japan
 - 15.9.1 Sepsis - Market Size
 - 15.9.1.1 Market Size (2018-2023)
 - 15.9.1.2 Market Forecast (2024-2034)
 - 15.9.2 Sepsis - Market Size by Therapies
 - 15.9.2.1 Market Size by Therapies (2018-2023)
 - 15.9.2.2 Market Forecast by Therapies (2024-2034)
 - 15.9.3 Sepsis - Access and Reimbursement Overview

16 SEPSIS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS

17 SEPSIS MARKET - SWOT ANALYSIS

- 17.1 Strengths
- 17.2 Weaknesses
- 17.3 Opportunities
- 17.4 Threats

18 SEPSIS MARKET – STRATEGIC RECOMMENDATIONS

19 APPENDIX

I would like to order

Product name: Sepsis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Product link: <https://marketpublishers.com/r/S64F0AEE1F68EN.html>

Price: US\$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/S64F0AEE1F68EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

